Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges for cancer vaccine development.

Z Tabi1, S Man

  • 1Department of Oncology and Palliative Medicine, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK. zsuzsanna.tabi@velindre-tr.wales.nhs.uk

Advanced Drug Delivery Reviews
|September 19, 2006
PubMed
Summary

First-generation human cancer vaccines show limited success in clinical trials. This review explores reasons for low efficacy and discusses challenges for developing effective future cancer vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.

ESMO open·2024
Same author

Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.

ESMO open·2024
Same author

ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients.

International journal of cardiology·2018
Same author

Rab35-dependent extracellular nanovesicles are required for induction of tumour supporting stroma.

Nanoscale·2018
Same author

Degree of Collaterals and Not Time Is the Determining Factor of Core Infarct Volume within 6 Hours of Stroke Onset.

AJNR. American journal of neuroradiology·2015
Same author

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

Leukemia·2015

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • The initial wave of human cancer vaccines has undergone extensive phase III clinical testing.
  • However, a significant number of these vaccines have not met the efficacy benchmarks required for regulatory approval and clinical deployment.

Purpose of the Study:

  • To critically review the underlying mechanisms contributing to the limited clinical responses observed with current cancer vaccines.
  • To identify and discuss the key challenges that impede the development of more effective future cancer vaccines.

Main Methods:

  • Literature review of phase III clinical trial data for human cancer vaccines.
  • Analysis of immunological and biological mechanisms influencing vaccine efficacy.
  • Synthesis of challenges reported in vaccine development research.

Related Experiment Videos

Main Results:

  • Several factors contribute to the suboptimal efficacy of existing cancer vaccines.
  • Significant hurdles exist in areas such as tumor antigen selection, delivery systems, and overcoming the immunosuppressive tumor microenvironment.

Conclusions:

  • The limited success of early human cancer vaccines necessitates a deeper understanding of immune evasion strategies employed by tumors.
  • Addressing the identified challenges is crucial for advancing the design and clinical translation of next-generation cancer immunotherapies.